Chinese Cancer Screening Firm Triples in Hong Kong IPO Debut

Chinese cancer screening biotech firm New Horizon Health Ltd. more than tripled on its Hong Kong debut on Thursday, notching the biggest first-day rise in the city’s history for initial public offerings raising at least HK$2 billion ($258 million).

New Horizon Health closed at HK$84, up 215% from the offer price of HK$26.66, which was already at the upper end of a marketed range. The biotech company raised $263 million in the IPO.

Chinese Cancer Screening Firm Triples in Hong Kong IPO Debut

Thursday’s pop shows that the IPO frenzy that’s gripped Hong Kong is intact, coming two weeks after short-video company Kuaishou Technology leaped 161% in its debut, the second-best ever for an IPO over $1 billion in the world.

Over 1 million Hong Kong investors put in orders worth some HK$844 billion for Qiming Venture Partners-backed New Horizon Health’s IPO. That represents a subscription rate of 4,133 times, the second-highest on record after Most Kwai Chung’s 2018 IPO, according to data compiled by Bloomberg.

First-time share sales have had their best start to the year on record in Asia, helped by Kuaishou’s mammoth offering and fueled by markets awash with liquidity, a stock rally, as well as hordes of retail investors bidding for shares. The dizzying first-day pops as well as the flurry of IPOs by blank-cheque companies in the U.S. have led some to warn of overheated markets.

©2021 Bloomberg L.P.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.